CCL22 and systemic sclerosis: In 54 SSc patients, there were significantly increased serum levels of IL-6, TNF-α, monocyte chemoattractant protein 1 (MCP1) (cancer-promoting), but also reduced IFN-γ and macrophage derived chemokine (MDC) (cancer-suppressive).